Maternal SepsisNCT05730387
Smart Discharges for Mom & Baby
An observational study of Maternal Sepsis and Neonatal Sepsis, run by University of British Columbia at 1 site in Canada.
Trial summary
This study aims to build a predictive algorithm that identifies mother-newborn dyads most at risk of death or complications in the 6 weeks after birth. The investigators will conduct a multi-site cohort study with 7,000 dyads in Uganda and engage with local stakeholders (e.g., patients, healthcare workers, and health… Read more about this study
- Who is it for?
- Ages 12 years and older, women only
- Conditions the study is for
- Maternal Sepsis, Neonatal Sepsis
- What is being tested?
- Observational only
- How many people
- 7,182 participants
- Where
- 1 siteCanada
- Study dates
- 14 Apr 2022to 30 Apr 2024
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study population represents women living within the catchments of two study hospitals (Mbarara Regional Referral Hospital and Jinja Regional Referral Hospital) in Uganda, who present for delivery.
Who may be able to join
- Women and adolescent girls aged 12 and above delivering a single or multiple babies at the study hospital during the active recruitment phase.
Who cannot join
- Inability, for whatever reason, to provide informed consent.
- Language barrier
- Mother is from a refugee camp
- Mother has no access to phone or other means for follow-up
- Mother lives outside of hospital catchment area
Trial locations and contacts
1 site in 1 country.
Canada1 site
BC Children's Hospital Research Institute
Vancouver, British Columbia, V5Z 2X8
About this study
Official title: Smart Discharges for Mom & Baby: Saving Mother-newborn Dyads by Developing a Predictive Risk Model to Identify Vulnerable Dyads and Guide Delivery of Evidence-based, Locally-informed Interventions for Targeted Post-discharge Care
This study aims to build a predictive algorithm that identifies mother-newborn dyads most at risk of death or complications in the 6 weeks after birth. The investigators will conduct a multi-site cohort study with 7,000 dyads in Uganda and engage with local stakeholders (e.g., patients, healthcare workers, and health policy-makers) to develop an evidence-based bundle of interventions that address key practice gaps and the critical factors leading to death and complications in these dyads. In the investigator's epidemiological study of post-delivery post-discharge outcomes in 3,236 dyads in Uganda (2017-2020), results indicated that most newborn and maternal readmissions were due to infectious illness (i.e. sepsis, surgical site infections, malaria), and primarily occurred early in the post-discharge period. Thus, the focus of this study will be identifying interventions that target these common and early outcomes, for both mothers and newborns, using World Health Organization recommendations, patient and caregiver experiences, and stakeholder recommendations. If successful, results will inform the next steps of this project, which is the external validation of the model and clinical evaluation of a personalized approach to improving health outcomes and health-seeking behaviour for mothers and newborns.
Read the detailed description
PURPOSE
Neonatal outcomes are highly correlated with the health of the mother, an example of this is shown repeatedly by poor rates of survival of infants after maternal death. Prediction of risk, based on the mother and infant as a pair, is a major gap in current research and yet vital to the survival of both the mom and the infant. Thus, maternal and child health outcomes can be improved by identifying both mothers and babies at increased risk of mortality or serious morbidity after hospital discharge and allocating scarce resources for targeted follow-up to those most vulnerable. This allows the investigators to not only improve health outcomes but benefits the health system with efficient use of resources.
JUSTIFICATION
Since 2011, the investigators have been working with partners in Uganda to develop, validate, and implement an innovative program for children under 5 years who have been discharged following hospitalization for suspected sepsis. In this research and implementation program, called Smart Discharges, healthcare workers use an individualized risk prediction score to identify children at high risk of death or complications after discharge from a hospital following treatment for suspected sepsis. They can then use this score to guide the intensity of a counselling and community-referral program. While all participants receive counselling, only those above a certain risk threshold receive down-referrals to community health facilities. The investigators have shown that this approach may reduce post-discharge child mortality after in-hospital treatment for suspected sepsis by as much as 30%. Now, the investigators are working to expand their innovative precision public health approach to improving post-discharge care for mother-newborn dyads.
Findings will inform the development an evidence-based bundle of care for both the mother and newborn. This package will ensure that low-risk mother-infant pairs receive less burdensome (yet pragmatic and feasible) postpartum care, while high risk pairs receive a more extensive bundle of interventions (such as education, nutrition, healthcare interaction and community support). The Smart Discharges for Mom \& Baby package will include support targeting aspects of both clinical and emotional wellbeing. Additional extensions of this work will include validating the risk models in women who deliver at home or suffer a stillbirth to ensure that more women and babies can benefit from the proposed intervention.
HYPOTHESIS
Maternal and infant characteristics collected at the time of discharge following a facility delivery can predict the risk of maternal or neonatal death or need for re-admission within six weeks of birth.
OBJECTIVE
The primary objective is to inform the development of an integrated maternal and newborn risk-based post-discharge care program. Specifically, the study aims to (1) develop and internally validate clinical risk prediction models for identifying dyads at high-risk of death or hospital readmission in the 6-week post-delivery post-discharge period, and (2) identify gaps and opportunities during in-hospital, discharge, and post-discharge care to inform the future development of an evidence-and risk-based bundle of interventions to improve postnatal care (PNC) for dyads.
DESIGN
This is a mixed-methods study using both quantitative and qualitative techniques to explore and map the current postnatal discharge processes in Uganda using data from two distinct hospital settings.
- Phase I) The team will conduct an observational cohort study informed through direct observation of the mother and newborn dyad prior to facility discharge and after delivery and follow-up telephone interviews conducted at six-weeks post-discharge.
- Phase II) The team will conduct journey mapping with a subset of dyads enrolled in the observational cohort using direct observation and follow-up telephone interviews.
- Phase III) The team will conduct a process mapping exercise using focus group discussion methodology with select facility staff.
- Phase IV) The team will conduct focus group discussions with a subset of mothers enrolled in the observational cohort, as well as their family members.
STATISTICAL ANALYSIS
Quantitative analysis: The investigators will summarize all risk factors for mothers and newborns that do and do not experience poor outcomes and estimate univariate associations. For newborns, data will be reported by sex. Derivation of prediction models will be based on optimization of the area under the receiver operating curve (AUROC) and specificity across a variety of modeling and variable selection approaches (e.g., logistic regression, elastic net, support vector machines). Model performance will be based on appropriate re-sampling techniques for internal validation (e.g., cross-validation, bootstrapping). Focus will be on developing parsimonious predictive models (e.g., 5-10 predictor variables) with high sensitivity (>80%). AUROC, sensitivity, and specificity will be reported for each model, along with positive and negative predictive values. Site specific metrics will be compared to ensure consistency across settings, and re-calibration may be considered if individual site performance is lower than expected. Finally, the investigators will assess combined sensitivity and specificity when each individual model is applied to the dyad. Outside of prediction modelling, the sample size will allow the investigators to detect an odds ratio of at least 1.30 for a given risk factor with 80% power and 5% significance and relative precision of 25%. Statistical analysis of quantitative data from journey mapping observation surveys and patient interviews will be performed using R Statistical software to obtain descriptive statistics of the frequency and distribution of each variable.
Qualitative Analysis: the investigators will analyze data collected descriptively and report summary statistics. A diagram of the discharge process will be developed, identifying key areas for improvement during the peri-discharge and post-discharge process. Focus group discussion data will be analyzed using a framework method, which allows themes to be developed inductively from participants and deductively from existing literature. Through an iterative process, transcripts will be coded and analyzed for descriptive and interpretive themes using NVivo. Descriptive themes include barriers to care and post-discharge health-seeking behaviour, while interpretive themes focus on caregiver perspectives of maternal and neonatal death and the role of the health system. The investigators will generate frequencies to describe reported medical symptoms, health-seeking behaviour, and barriers to care, and summarize common themes. Member checking will be used to improve the validity of the results, creating a summary document of the main findings that will be reviewed by health workers who participated in the focus groups. Feedback from patients and families will be obtained over telephone with research nurses who will explain the main findings verbally.
- Conditions
- Maternal Sepsis, Neonatal Sepsis
- Being tested
- Observational only
- Keywords
- maternal health, neonatal health, patient discharge, post-natal care
- Medical subject headings
- Pregnancy Complications, Infectious, Neonatal Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational onlyOther
This is a non-interventional study
| Study group | Role | What they receive |
|---|---|---|
| mother and newborn dyads | We will recruit 6700 mother and newborn dyads from the two participating hospitals. We will continue to follow-up with all patients enrolled in the study until 6 weeks (42 days) post delivery. Receives: Other: Observational only |
What is being measured
The primary outcome is the main question the study is designed to answer.
Post-discharge Readmission or Mortality
Composite rate of maternal or neonatal death or re-admission within 6 weeks following delivery
Measured: 6 weeks following delivery
Secondary outcomes (2)
Post-natal Care Visits
% patients who reported attending at least one post-natal care visits within 6 weeks following delivery
Measured: 6 weeks following delivery
Post-discharge Health Seeking
% of patients who reported seeking post-discharge care within 6 weeks following delivery
Measured: 6 weeks following delivery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Feb 2023
- Study start14 Apr 2022
- Primary completion31 Aug 2023
- Study completion30 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Maternal SepsisStudies of the same condition, open and under way.
- More trials run by University of British ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 7,182 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of British Columbia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Matthew Wiens, University of British Columbia
- Investigators
- Matthew O Wiens, PharmD, PhD, Principal investigator, University of British Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05730387
- Sponsor's protocol ID
- H21-03709
- Status last verified
- Mar 2025
- First submitted
- 9 Dec 2022
- Last updated
- 10 Apr 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: After the study period, a de-identified copy of the data will be prepared for deposition in a repository with open access with proper governance mechanisms. We will make every effort to prevent re-identification of subjects by coding data that has the potential of being identifiable. For example, we will convert all dates into meaningful decimal numbers (date of birth into days since birth and date of recruitment will be reduced to month of recruitment) and all locations will be coded into data that is useful but not specific (such as address converted to distance and direction from facility). We will ensure that data elements with small numbers of subjects (less than 10) will be coded or lumped to avoid identification. The de-identified study data will be made available using a data hosting service (e.g., Dataverse, Vivli, etc.)
Publications
Wiens MO, Trawin J, Pillay Y, Nguyen V, Komugisha C, Kenya-Mugisha N, Namala A, Bebell LM, Ansermino JM, Kissoon N, Payne BA, Vidler M, Christoffersen-Deb A, Lavoie PM, Ngonzi J. Prognostic algorithms for post-discharge readmission and mortality among mother-infant dyads: an observational study protocol. Front Epidemiol. 2023 Nov 29;3:1233323. doi: 10.3389/fepid.2023.1233323. eCollection 2023.
PubMed 38455948
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Smart Discharges for Mom & Baby: Saving Mother-newborn Dyads by Developing a Predictive Risk Model to Identify Vulnerable Dyads and Guide Delivery of Evidence-based, Locally-informed Interventions for Targeted Post-discharge Care
- ClinicalTrials.gov ID
- NCT05730387
- Acronym / sponsor ID
- H21-03709
- Conditions
- Maternal Sepsis, Neonatal Sepsis
- Keywords
- maternal health, neonatal health, patient discharge, post-natal care
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 7,182 participants (actual)
- Lead sponsor
- University of British ColumbiaUniversity, hospital or other
- Study start
- 14 Apr 2022 (actual)
- Primary completion
- 31 Aug 2023 (actual)
- Study completion
- 30 Apr 2024 (actual)
- First posted
- 15 Feb 2023 (actual)
- Results
- Posted 10 Apr 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to build a predictive algorithm that identifies mother-newborn dyads most at risk of death or complications in the 6 weeks after birth. The investigators will conduct a multi-site cohort study with 7,000 dyads in Uganda and engage with local stakeholders (e.g., patients, healthcare workers, and health policy-makers) to develop an evidence-based bundle of interventions that address key practice gaps and the critical factors leading to death and complications in these dyads. In the investigator's epidemiological study of post-delivery post-discharge outcomes in 3,236 dyads in Uganda (2017-2020), results indicated that most newborn and maternal readmissions were due to infectious illness (i.e. sepsis, surgical site infections, malaria), and primarily occurred early in the post-discharge period. Thus, the focus of this study will be identifying interventions that target these common and early outcomes, for both mothers and newborns, using World Health Organization recommendations, patient and caregiver experiences, and stakeholder recommendations. If successful, results will inform the next steps of this project, which is the external validation of the model and clinical evaluation of a personalized approach to improving health outcomes and health-seeking behaviour for mothers and newborns.
Detailed description
PURPOSE
Neonatal outcomes are highly correlated with the health of the mother, an example of this is shown repeatedly by poor rates of survival of infants after maternal death. Prediction of risk, based on the mother and infant as a pair, is a major gap in current research and yet vital to the survival of both the mom and the infant. Thus, maternal and child health outcomes can be improved by identifying both mothers and babies at increased risk of mortality or serious morbidity after hospital discharge and allocating scarce resources for targeted follow-up to those most vulnerable. This allows the investigators to not only improve health outcomes but benefits the health system with efficient use of resources.
JUSTIFICATION
Since 2011, the investigators have been working with partners in Uganda to develop, validate, and implement an innovative program for children under 5 years who have been discharged following hospitalization for suspected sepsis. In this research and implementation program, called Smart Discharges, healthcare workers use an individualized risk prediction score to identify children at high risk of death or complications after discharge from a hospital following treatment for suspected sepsis. They can then use this score to guide the intensity of a counselling and community-referral program. While all participants receive counselling, only those above a certain risk threshold receive down-referrals to community health facilities. The investigators have shown that this approach may reduce post-discharge child mortality after in-hospital treatment for suspected sepsis by as much as 30%. Now, the investigators are working to expand their innovative precision public health approach to improving post-discharge care for mother-newborn dyads.
Findings will inform the development an evidence-based bundle of care for both the mother and newborn. This package will ensure that low-risk mother-infant pairs receive less burdensome (yet pragmatic and feasible) postpartum care, while high risk pairs receive a more extensive bundle of interventions (such as education, nutrition, healthcare interaction and community support). The Smart Discharges for Mom \& Baby package will include support targeting aspects of both clinical and emotional wellbeing. Additional extensions of this work will include validating the risk models in women who deliver at home or suffer a stillbirth to ensure that more women and babies can benefit from the proposed intervention.
HYPOTHESIS
Maternal and infant characteristics collected at the time of discharge following a facility delivery can predict the risk of maternal or neonatal death or need for re-admission within six weeks of birth.
OBJECTIVE
The primary objective is to inform the development of an integrated maternal and newborn risk-based post-discharge care program. Specifically, the study aims to (1) develop and internally validate clinical risk prediction models for identifying dyads at high-risk of death or hospital readmission in the 6-week post-delivery post-discharge period, and (2) identify gaps and opportunities during in-hospital, discharge, and post-discharge care to inform the future development of an evidence-and risk-based bundle of interventions to improve postnatal care (PNC) for dyads.
DESIGN
This is a mixed-methods study using both quantitative and qualitative techniques to explore and map the current postnatal discharge processes in Uganda using data from two distinct hospital settings.
- Phase I) The team will conduct an observational cohort study informed through direct observation of the mother and newborn dyad prior to facility discharge and after delivery and follow-up telephone interviews conducted at six-weeks post-discharge.
- Phase II) The team will conduct journey mapping with a subset of dyads enrolled in the observational cohort using direct observation and follow-up telephone interviews.
- Phase III) The team will conduct a process mapping exercise using focus group discussion methodology with select facility staff.
- Phase IV) The team will conduct focus group discussions with a subset of mothers enrolled in the observational cohort, as well as their family members.
STATISTICAL ANALYSIS
Quantitative analysis: The investigators will summarize all risk factors for mothers and newborns that do and do not experience poor outcomes and estimate univariate associations. For newborns, data will be reported by sex. Derivation of prediction models will be based on optimization of the area under the receiver operating curve (AUROC) and specificity across a variety of modeling and variable selection approaches (e.g., logistic regression, elastic net, support vector machines). Model performance will be based on appropriate re-sampling techniques for internal validation (e.g., cross-validation, bootstrapping). Focus will be on developing parsimonious predictive models (e.g., 5-10 predictor variables) with high sensitivity (>80%). AUROC, sensitivity, and specificity will be reported for each model, along with positive and negative predictive values. Site specific metrics will be compared to ensure consistency across settings, and re-calibration may be considered if individual site performance is lower than expected. Finally, the investigators will assess combined sensitivity and specificity when each individual model is applied to the dyad. Outside of prediction modelling, the sample size will allow the investigators to detect an odds ratio of at least 1.30 for a given risk factor with 80% power and 5% significance and relative precision of 25%. Statistical analysis of quantitative data from journey mapping observation surveys and patient interviews will be performed using R Statistical software to obtain descriptive statistics of the frequency and distribution of each variable.
Qualitative Analysis: the investigators will analyze data collected descriptively and report summary statistics. A diagram of the discharge process will be developed, identifying key areas for improvement during the peri-discharge and post-discharge process. Focus group discussion data will be analyzed using a framework method, which allows themes to be developed inductively from participants and deductively from existing literature. Through an iterative process, transcripts will be coded and analyzed for descriptive and interpretive themes using NVivo. Descriptive themes include barriers to care and post-discharge health-seeking behaviour, while interpretive themes focus on caregiver perspectives of maternal and neonatal death and the role of the health system. The investigators will generate frequencies to describe reported medical symptoms, health-seeking behaviour, and barriers to care, and summarize common themes. Member checking will be used to improve the validity of the results, creating a summary document of the main findings that will be reviewed by health workers who participated in the focus groups. Feedback from patients and families will be obtained over telephone with research nurses who will explain the main findings verbally.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| mother and newborn dyads | – | Other: Observational onlyWe will recruit 6700 mother and newborn dyads from the two participating hospitals. We will continue to follow-up with all patients enrolled in the study until 6 weeks (42 days) post delivery. |
Who may qualify
- Ages
- 12 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study population represents women living within the catchments of two study hospitals (Mbarara Regional Referral Hospital and Jinja Regional Referral Hospital) in Uganda, who present for delivery.
Key inclusion criteria (1 listed)
- Women and adolescent girls aged 12 and above delivering a single or multiple babies at the study hospital during the active recruitment phase.
Key exclusion criteria (5 listed)
- Inability, for whatever reason, to provide informed consent.
- Language barrier
- Mother is from a refugee camp
- Mother has no access to phone or other means for follow-up
- Mother lives outside of hospital catchment area
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational onlyThis is a non-interventional study | Other | mother and newborn dyads |
Primary outcome
Post-discharge Readmission or Mortality
Time frame: 6 weeks following delivery
Composite rate of maternal or neonatal death or re-admission within 6 weeks following delivery
2 secondary outcomes
Post-natal Care Visits
Time frame: 6 weeks following delivery
Post-discharge Health Seeking
Time frame: 6 weeks following delivery
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 38455948Wiens MO, Trawin J, Pillay Y, Nguyen V, Komugisha C, Kenya-Mugisha N, Namala A, Bebell LM, Ansermino JM, Kissoon N, Payne BA, Vidler M, Christoffersen-Deb A, Lavoie PM, Ngonzi J. Prognostic algorithms for post-discharge readmission and mortality among mother-infant dyads: an observational study protocol. Front Epidemiol. 2023 Nov 29;3:1233323. doi: 10.3389/fepid.2023.1233323. eCollection 2023.
- Individual participant dataSharing planned: Yes. After the study period, a de-identified copy of the data will be prepared for deposition in a repository with open access with proper governance mechanisms. We will make every effort to prevent re-identification of subjects by coding data that has the potential of being identifiable. For example, we will convert all dates into meaningful decimal numbers (date of birth into days since birth and date of recruitment will be reduced to month of recruitment) and all locations will be coded into data that is useful but not specific (such as address converted to distance and direction from facility). We will ensure that data elements with small numbers of subjects (less than 10) will be coded or lumped to avoid identification. The de-identified study data will be made available using a data hosting service (e.g., Dataverse, Vivli, etc.)
Related trials for Maternal Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruiting
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
Preeclampsia, Hypertensive Disorder of Pregnancy
Recruiting
Implementation Models for Blood Pressure Monitoring in Pregnancy and Postpartum: Connected MOM Plus
Maternal Health Care, Hypertensive Disorder of Pregnancy
Recruiting
Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV
Hiv, Transmission Vertical
Not yet recruitingPhase 4
PROMab Trial: Ampicillin With or Without Gentamicin for Term Prelabour Rupture of Membranes
Rupture of Membranes Prior to Onset of Labor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Matthew O Wiens, PharmD, PhD principal investigator
University of British Columbia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Maternal Sepsis and Neonatal Sepsis, run by University of British Columbia at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Apr 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Post-discharge Readmission or Mortality (time frame: 6 weeks following delivery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05730387, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2025.